Although the total amount of plasma proteins adsorbed on nanoparticles does not determine C3 deposition efficiency, the biomolecule corona per se enhances immunoglobulin binding to all nanoparticle types. We therefore show that natural antibodies represent a link between biomolecule corona and C3 opsonization, and may determine individual complement responses to nanomedicines.
A dvances in the development of engineered nanomaterials have resulted in several nanopharmaceuticals for clinical use and many more in the clinical development stage 1 . Nevertheless, there are still important issues that need to be resolved, including non-specific clearance of functional nanoparticles by different immune cell types, and life-threatening infusion reactions that occur in some patients receiving nanopharmaceuticals 2 . Better understanding of the immune mechanisms that lead to the clearance and toxicities of nanomaterials in general, and of clinically approved nanopharmaceuticals in particular, should be one of the primary tasks in nanomedicine research and development. Plasma protein adsorption has long been debated to be an important factor affecting the functionality of intravenously injected nanomedicines [3] [4] [5] . Recent studies have demonstrated the role of adsorbed proteins in nanoparticle targeting 6 , immune responses 7 and intracellular toxicity 8, 9 . Among the most interesting immunological constituents of the protein corona formed around a nanoparticle are components of the complement system. Upon activation, all three pathways (alternative, classical and lectin) of the complement system converge at the point at which the third complement protein, C3, is cleaved through assembly of C3 convertases, which generate a common set of effector molecules including C3a and C3b 2,10 . The latter fragment covalently binds to activating surfaces, thereby aiding their recognition by leukocytes and macrophages, a process termed opsonization. C3b is further involved in surface assembly of C5 convertase, which in turn cleaves the fifth complement protein (C5) into C5a and C5b, thereby triggering activation of the terminal pathway of the complement system. Both C3a and C5a are potent anaphylatoxins, which activate mast cells and other immune cells, and therefore induce proinflammatory reactions. Although the role of complement in infusion reactions to nanomedicine is being debated 11 , there is a concern that uncontrolled complement activation may affect the disease outcome and nanomedicine performance in general [12] [13] [14] .
As opsonization with C3 is the central event in complement cascade and immune recognition, mechanisms of C3 deposition on nanomedicines are of special interest for biological performance 2 . Earlier, we found that C3b preferentially binds to the biomolecule corona on SPIO nanoworms in both plasma and serum. Moreover, C3 deposition was enhanced in the presence of the protein corona, underlying the dependence of the complement activation on other, less characterized corona components 15 . SPIO is an important magnetic resonance imaging contrast agent and a component of multifunctional theranostic nanomedicines for imaging and treatment 16, 17 . Furthermore, we demonstrated a significant between-subject variability in levels of C3 deposition on SPIO nanoworms, as well as on clinically approved nanomedicines including the intravenous iron supplement Feraheme, PEGylated liposomal doxorubicin LipoDox, and non-PEGylated liposomal irinotecan Onivyde 18 . We hypothesize that complement activation efficiency by these nanomaterials is determined by differences in composition of the biomolecule corona. Among many plasma proteins, natural antibodies such as immunoglobulin G (IgG) and immunoglobulin M (IgM) are known to bind to foreign and self-antigens, and modulate complement activation through the three complement pathways [19] [20] [21] [22] . Here we demonstrate that binding of only a few immunoglobulin molecules, and specifically IgG, determines the efficiency of C3 deposition on the above-mentioned nanomaterials in plasma and sera of healthy donors and in plasma of cancer patients, regardless of the complement activation pathway. Moreover, we demonstrate that the presence of the biomolecule corona enhances IgG binding to all tested nanomaterials. These results establish natural antibodies as a critical factor that determines the efficiency of complement activation in different subjects and by different nanomaterials, and could promote development of clinically approved nanoparticles with an improved safety profile.
Immunoglobulins promote C3 deposition
We prepared SPIO nanoworms, ~110 nm hydrodynamic diameter, coated with 20 kDa dextran ( Fig. 1a and Supplementary Table 1 ), as described previously 15, 23 . To understand the role of immunoglobulins in C3 deposition on nanoparticles, we pretreated lepirudin plasma of three healthy donors with protein A sepharose beads. Protein A strongly binds human IgG but weakly binds human IgM. Following this pretreatment, there was minimal detectable level of immunoglobulin in plasma, but the quantities of C1q and C3 were close to physiological levels ( Supplementary Fig. 1 ). According to Western blot analysis ( Fig. 1b and Supplementary Fig. 2 ), the deposition of C3 (predominantly iC3b) on nanoworms was decreased in all depleted plasma, and addition of polyclonal human IgG restored C3 deposition. Compared with Western blot, dot blot is a more quantitative assay to measure changes in the deposition of proteins on nanoparticle surfaces ( Supplementary Fig. 3 ) 15, 18, 23, 24 . Again, dot blot analysis in sera of seven healthy donors ( Fig. 1c ) confirmed not only a significant decrease in C3 opsonization in depleted sera (P < 0.0001) but also a significant increase in C3 opsonization (P < 0.0001) on addition of polyclonal human IgG. Because protein A can potentially deplete some IgM, we tested the ability of purified polyclonal IgM to restore complement C3 deposition. Addition of IgM to three protein-A-depleted sera only marginally increased the level of C3 deposited on SPIO nanoworms ( Supplementary Fig. 4 ). Also, addition of a monoclonal human IgG (trastuzumab) to the depleted sera had no significant effect on C3 deposition ( Fig. 1d ). Lastly, measurement of bound immunoglobulin and C3 in sera of 12 healthy subjects (7 females and 5 males) showed a significant association between levels of immunoglobulin and C3 ( Fig. 1e , P = 0.0002). These data suggest that immunoglobulins, in particular IgG class, play an important role in the efficiency of complement C3 deposition on SPIO nanoworms.
Surface-adsorbed antibodies can promote C3 opsonization through all three complement pathways (Fig. 1f ). The classical pathway involves C1q binding to the Fc portion of closely adjacent antibodies 25 , whereas the lectin pathway may be triggered by binding of mannosebinding lectin, collectins and ficolins to sugar residues on IgG 26, 27 . In addition to these, IgG can enhance C3 deposition directly by acting as a scaffold for initial C3b binding and subsequently amplify C3b deposition through the alternative pathway turnover 20, 21 . C3 deposition in the plasma of three donors (same donors as in Fig. 1b ) was not inhibited by the classical pathway inhibitor C1INH ( Supplementary Fig. 5 ), suggesting minimal involvement of the classical pathway in these samples. Measurements of C3 deposition in a larger cohort of serum samples (n = 10 healthy donors) showed a significant decrease after treatment with EGTA/Mg 2+ ( Fig. 1g ; P < 0.0001) in 5 out of 10 sera, suggesting a role for calcium-sensitive pathways in some of the samples, and predominantly the alternative pathway in other samples. EDTA (a global inhibitor of all complement pathways) inhibited C3 deposition by over 80% ( Fig. 1g ; P < 0.0001). Previously, we demonstrated the involvement of the lectin pathway in complement activation by SPIO nanoworms 28 . Nanoparticles can trigger complement activation through different pathways in different subjects 29 , but notably immunoglobulins play a universal role in all tested samples regardless of the activation pathway. Factor H (fH) is a negative serum regulator of complement convertase that binds to C3b, promotes cleavage of C3b and disassembly of the alternative pathway convertase. Genetic mutations in fH often lead to deficient binding and inhibition, and hence differences in complement reactivity in general population (termed complotype) 30 . We measured binding of fH and C3 to SPIO nanoworms in 12 healthy sera (7 females and 5 males). The amount of deposited C3 directly correlated with the amount of deposited fH ( Fig. 1h ; P = 0.0003), consistent with the ability of fH to bind the AP convertase. Addition of 100 µ g ml −1 of purified fH to three sera ( Fig. 1i , dot blot) and three plasma samples ( Supplementary Fig. 6 , Western blot) resulted in a minimal decrease in C3 opsonization of SPIO nanoworms, thereby ruling out the role of fH in the observed variability in C3 opsonization.
Feraheme is a clinically approved monocrystalline ultrasmall SPIO coated with a reduced, negatively charged 10 kDa carboxymethyl dextran ( Fig. 2a and Supplementary Table 1 ). Previously, we demonstrated significant between-subject variability of C3 binding to Feraheme 18 . C3 opsonization of Feraheme was significantly decreased in three protein-A-depleted plasma samples ( Fig. 2b and Supplementary Fig. 2 ) and three sera ( Fig. 2c ; P = 0.0029), and reconstitution with polyclonal human IgG increased C3 opsonization in all plasma ( Fig. 2b ) and sera ( Fig. 2c ; P = 0.0315). In a healthy cohort of 12 sera (6 females and 6 males), the correlation between immunoglobulin and C3 binding to Feraheme was significant ( Fig. 2d ; P = 0.002). C3 opsonization was not inhibited in three plasma samples treated with C1INH ( Supplementary Fig. 7 ) and was not significantly inhibited in sera treated with EGTA/Mg 2+ ( Fig. 2e ; P = 0.99). These data indicate that immunoglobulins trigger C3 opsonization of Feraheme predominantly through the alternative pathway. Because Feraheme is administered as an iron supplement to cancer patients 31 , we tested the effect of IgG on C3 deposition in plasma from metastatic breast cancer patients. Thus, we obtained matched lepirudin-anticoagulated and EDTAanticoagulated plasma from a cohort of eight patients with breast cancer (description of patients is in Supplementary Table 2 ). Depletion of immunoglobulins from lepirudin plasma significantly decreased C3 opsonization of Feraheme ( Fig. 2f ; P = 0.0016), and reconstitution with purified polyclonal IgG restored or increased complement activation in all samples ( Fig. 2f ; P < 0.0001). There was little or no C3 detected on particles incubated in EDTA plasma ( Fig. 2f ).
Next, we tested the role of immunoglobulins in C3 opsonization of clinically approved liposomal nanomedicines. PEGylated liposomal doxorubicin (LipoDox, Doxil) is a ~100 nm liposome encapsulating approximately 30,000 doxorubicin molecules ( Fig. 3a and Supplementary Table 1 ) and has been used over 20 years for cancer therapy 32 . C3 opsonization of LipoDox was significantly reduced in three protein-A-depleted plasma ( Fig. 3b and Supplementary Fig. 2 ) and four sera ( Fig. 3c ; for dot blot P < 0.0001), and reconstitution with polyclonal human IgG restored C3 opsonization in both plasma ( Fig. 3b ) and sera ( Fig. 3c ; P < 0.0001). In a cohort of 12 healthy sera (8 females and 4 males), there was a non-significant but suggestive association between levels of immunoglobulin and C3 ( Fig. 3d ; P = 0.062). C3 opsonization was not inhibited by C1INH in three tested plasma samples ( Supplementary Fig. 7 ), whereas C3 opsonization was inhibited by 30-60% by EGTA/Mg 2+ in five sera ( Fig. 3e ; P < 0.0001), suggesting that LipoDox triggers complement activation in sera via the alternative pathway with some involvement of calcium-dependent pathways. Involvement of the alternative and the lectin pathways in complement activation by PEG has been reported before 33 . In the cohort of lepirudin plasma from eight breast cancer patients, depletion of immunoglobulins significantly decreased C3 opsonization of LipoDox in all samples ( Fig. 3f ; P < 0.0001), and C3 deposition was increased or completely restored upon IgG reconstitution in five out of eight samples ( Fig. 3f ; P = 0.0199). Notably, complete restoration of complement activation in samples 29 and 51 was achieved with a different batch of polyclonal IgG, suggesting that this batch contained IgG clones that could efficiently activate complement. Onivyde is a 120 nm non-PEGylated liposome internally loaded with ~70,000 molecules of irinotecan ( Fig. 3g and Supplementary Table 1) , and was recently approved for gastrointestinal cancers 34 . Onivyde showed significant between-subject variability of C3 opsonization 18 . C3 opsonization of Onivyde was decreased in two out of three protein-A-depleted plasma samples ( Fig. 3h and Supplementary Fig. 2 ) and in three depleted sera ( Fig. 3i ; P = 0.0018), and reconstitution with polyclonal human IgG restored or increased C3 opsonization in tested plasma samples ( Fig. 3h ) and sera ( Fig. 3i ; P = 0.0253). In a cohort of 12 healthy sera (5 females and 7 males), there was a significant association between levels of bound immunoglobulin and C3 ( Fig. 3j ; P = 0.0003). C1INH did not decrease C3 opsonization in all the plasma samples ( Supplementary Fig. 7 ), whereas EGTA/Mg 2+ partially decreased it in two out of five sera ( Fig. 3k ; P = 0.0264), suggesting that immunoglobulins trigger complement predominantly by the alternative pathway. In the cohort of lepirudin plasma from eight breast cancer patients, depletion of immunoglobulins significantly decreased C3 opsonization of Onivyde in all samples ( Fig. 3l ; p < 0.0001), and C3 deposition was increased upon IgG reconstitution in seven out of eight samples ( Fig. 3l ; p < 0.0001).
We previously found that C3 covalently binds to adsorbed serum proteins on the nanoparticle surface 15 . To determine whether C3 attacks surface-adsorbed immunoglobulins, protein coronas formed in six healthy sera were eluted from SPIO nanoworms with 2% SDS buffer, and analysed on a non-reducing gel (protein-C3 complexes should run as high-molecular-weight bands) 35 . In most of the sera, the eluted immunoglobulin was localized in a highmolecular-weight fraction (300-500 kDa) that co-localized with C3 ( Fig. 4a , upper arrow), consistent with C3-IgG complexes as described previously 36 . In some samples, free IgG was also present (Fig. 4a , lower arrow). A similar result was obtained using lepirudin plasma samples from five healthy donors ( Supplementary Fig. 8 ). The fact that the majority of eluted C3 did not colocalize with IgG suggests that IgG serves as a trigger for C3 opsonization, rather than a sole scaffold for C3 binding. According to quantitative stoichiometric analysis of IgG and C3 binding in 12 sera ( Fig. 4b ), there are significantly more C3 molecules than IgG molecules per SPIO nanoworm (C3/IgG ratio 51 ± 17; P < 0.0001, two-sided t-test), 
Biomolecule corona promotes IgG binding to nanoparticles
We questioned whether other corona proteins besides immunoglobulin play a role in C3 opsonization. We incubated SPIO nanoworms with sera of six healthy donors and measured the total amount of bound protein. The amount of bound C3 did not correlate with the amount of non-C3 protein in the coronas ( Fig. 5a ; Pearson r 2 = 0.163; P = 0.4). Coronas with higher C3/particle density also contained a higher percentage of C3 ( Supplementary Fig. 9 ). These results clearly demonstrate that total bound protein does not determine the efficiency of C3 opsonization. At the same time, in the same six sera, the amount of C3 showed correlation with properdin, which is a positive regulator of the alternative pathway convertase 37 ( Supplementary Fig. 10 ). Shotgun proteomics of protein corona of SPIO nanoworms in six sera ( Fig. 5b ) and five lepirudin plasma samples (Fig. 5c ) showed enrichment with apolipoproteins, albumin, complement factors, clotting cascade factors, fibronectin, immunoglobulins, carrier proteins and other regulatory proteins. These proteins have been reported to bind to nanoparticles [38] [39] [40] . C1q was not detected on any corona, thereby excluding possible involvement of the classical pathway in complement activation. However, the corona obtained from sera incubations showed presence of MBL-C and/or MASP-1 (where MBL is mannose-binding lectin and MASP is MBL-associated serine protease). To test the role of key corona proteins in complement activation, SPIO nanoworms were briefly preincubated with fibrinogen, fibronectin, albumin, IgG, apolipoprotein B-100 (Apo-B), high-molecular-weight kininogens (HMWK), high-density lipoproteins (HDL), low-density lipoproteins (LDL), factor H and properdin, and then added (without washing step) to sera of healthy donors (Fig. 5d ). IgG promoted a three-fold increase in complement C3 deposition compared with non-preincubated particles (P < 0.0001). Fibronectin induced a minor increase in C3 deposition (P < 0.0001), whereas other tested proteins and lipoproteins did not enhance or decrease the C3 deposition (Fig. 5d ). The hallmark of natural antibodies is their ability to recognize self-epitopes on proteins, especially the denatured species 41 . We questioned whether protein corona aids the binding of IgG to nanoparticle surfaces. Purified human IgG was added to PBS, 50 mg ml −1 human serum albumin or protein-A-depleted sera (three healthy donors), and SPIO nanoworms, Feraheme, LipoDox or Onivyde were added next. As shown in Fig. 5e,f and Supplementary Fig. 11 , in PBS there was minimal binding of IgG to all nanoparticle types, except for LipoDox. Importantly, IgG did not bind to any nanoparticle type in presence of serum albumin, whereas IgG showed efficient binding in the presence of protein corona (Fig. 5e,f ).
Conclusions
In summary, we have demonstrated that in multiple sera and plasma samples, natural antibodies play the critical role in complement opsonization of diagnostic nanoparticles and clinically approved nanomedicines, regardless of the activation pathway. More specifically, antibody binding to nanoparticles was dependent on the biomolecule corona and the binding of a few antibody molecules was sufficient to trigger complement activation. Experiments with depleted plasma samples and sera showed that in some samples the levels of C3 could not be restored to the original levels on addition of polyclonal IgG (although sufficient quantities of C3 were present in such media). Indeed, non-specific deposition of antibodies may not necessarily trigger complement activation through any of the three complement pathways. In the case of the alternative pathway, C3b attack and the convertase assembly may strictly depend on specific antibody-epitope binding, where a few antibodies could trigger the process. Thus, the aforementioned results are likely to be due to different titre and/or absence of some specific immunoglobulin molecules in the polyclonal preparation and specific glycosylation patterns capable of triggering complement in the context of the adsorbed biomolecule corona. In terms of complement activation, this introduces considerable variability due to nanoparticle surface heterogeneity, surface defects and solvation patterns within a particular batch 42 , which in turn may control not only the extent of Free IgG is shown by the lower arrow. IgG and C3b standards were run in parallel (left two lanes). Note the presence of several high-molecular-weight bands for C3, suggesting binding to other corona proteins. The bulk of C3 is not bound to IgG. In the rightmost lane, there are more IgG-C3 complexes and also more total C3, whereas the leftmost serum lane shows the opposite. The experiment was repeated three times in serum and once in plasma ( Supplementary Fig. 7) . biomolecule deposition and retention, but also their projected conformation and hence epitope exposure, which becomes the rate-limiting factor in triggering alternative pathway activation. Therefore, between-subject variability might be due to subtle conformational differences in repertoire of nanoparticle-bound biomolecules and concomitant presence of a specific immunoglobulin titre against the exposed antigenic epitope. Although we demonstrated the role of IgG in complement activation by nanomedicines, we did not identify the responsible IgG subclasses and cannot exclude the role of other classes of immunoglobulins, which could play an important role in the efficiency of complement activation. Protein A is known to deplete serum/ plasma from IgG 1 , IgG 2 , IgG 3 and to some extent IgM 43 . Indeed, binding of naturally occurring IgM antibodies against a component of the pristine surface (for example, anti-PEG and antidextran IgM) 44 could trigger complement activation through the classical pathway. Among the tested cohort of donors and nanoparticles, however, we excluded a major role of the classical pathway in complement activation.
We excluded a direct and predominant IgG binding to the pristine surfaces, but the epitopes responsible for IgG docking are not known. However, in the case of liposomes, earlier studies have suggested a role for β -2-glycoprotein 1 deposition in subsequent anti-phospholipid antibody binding and eventual complement activation 45 . Proteomic studies may inadvertently over-generalize the role of nanoparticle protein/glycoprotein/lipoprotein corona in complement activation and immune performance. For instance, mass spectrometry cannot distinguish between non-specific immunoglobulin deposition and immunoglobulin bound to an antigenic epitope. Furthermore, IgG deposition on a nanoparticle through its Fc fragment may even suppress (or prevent) complement activation and delay nanoparticle clearance by macrophages in a manner similar to certain pathogenic microbes 43, 46, 47 .
Our results show that for most of the human subjects and nanoparticles tested, the alternative pathway was the predominant activation pathway. Based on our data and the available literature, we propose the following sequence of nanoparticle-mediated alternative activation by immunoglobulins ( Fig. 6) . A few immunoglobulin molecules recognise and bind the exposed antigenic epitopes of the protein corona. Nascent C3b attacks surface-bound immunoglobulin (alternatively, the latter may have already been attacked in the fluid phase, thereby bringing C3b to the particle surface) 36 . As a result of the initial C3b deposition, a few convertases (C3bBb-properdin complexes) assemble on the surface, thereby amplifying C3 cleavage near the nanoparticle surface, resulting in covalent binding of highly reactive C3b to reactive epitopes (for example, amino or hydroxyl moieties) of adsorbed plasma proteins (or other surfaceassociated molecules) 15 . The initial C3 seed hypothesis is further supported by earlier studies where cell surface-adsorbed IgG was shown to initially accommodate C3b molecules and the fact that IgG-bound C3b was protected up to 30-fold against inactivation by fluid-phase complement regulators factors H and I 48, 49 .
Identification of subsets of patients with enhanced propensity for immune reactions towards nanomedicines is a major task. Immunoglobulin binding can promote recognition by macrophages and modulate anaphylaxis 13 . It would be important to see whether natural antibody binding could serve as a broad biomarker of nanoparticle clearance and anaphylactic reactions. Such a biomarker could have tremendous value in the prediction of immune response towards nanomedicines in patients. In addition, developing strategies to block the binding of natural antibodies to biomolecular corona can open new opportunities to improve haemocompatibility and safety of nanomedicines.
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Methods
Materials. Linear dextran (15-25 kDa molecular weight) and iron salts were purchased from Sigma-Aldrich. Purified C3 (A113), fH (A137), C3b (A114), iC3b (A115), C1 inhibitor (A140) and properdin (A139) were purchased from Complement Technology. All proteins were aliquoted at 1 mg ml −1 and stored at − 80 °C. Every protein was exposed to no more than two freeze-thaw cycles. . Sera were processed as described by us previously 18 and stored in frozen aliquots at − 80 °C. Plasma was obtained by centrifugation of K 2 EDTA or lepirudin tubes at 5,000g for 20 min at room temperature immediately after the collection and stored in frozen aliquots at − 80 °C.
SPIO nanoworm synthesis.
Large SPIO nanoworms were synthesized from 15-25 kDa dextran, Fe(iii) chloride and Fe(ii) chloride in a modified Molday precipitation method in ammonia 50 as described by us previously 28 . The ratio between dextran and iron salts determined the final size of the nanoparticles 28 . Particles were resuspended in sterile water, filtered through 0.45 µ m filter and stored at 4 °C. Size (intensity weighted diameter) was determined using Zetasizer Nano ZS (Malvern Instruments). At least two batches were used in the study ( Supplementary Table 1 ).
Label-free mass spectrometry. SPIO nanoworms (200 µ l, 1 mg Fe ml −1 ) were incubated with six sera types or 5 lepirudin plasma samples (600 μ l each) for 15 min at 37 °C in Beckman 1.5 ml polyallomer tubes (Beckman-Coulter). Nanoparticles were washed 5 times with 1 ml PBS using Beckman Optima ultracentrifuge (TLA-100.3 rotor, 450,000g, 8 min, 4 °C). The proteins were eluted from nanoparticles by incubation in 2% SDS in PBS for 1 h at room temperature and additional ultracentrifugation. Nanoparticles were pelleted as described above, and the protein concentration in the supernatant was measured using BCA Protein Assay (Thermo Fisher). Sample was processed at the Proteomics and Metabolomics core facility at the Skaggs School of Pharmacy, University of Colorado, using a previously described filter-aided sample purification method 51 . The sample was separated with a C-18 reverse-phase nano liquid chromatography column (100 µ m × 150 mm, 3.0 µ m, 200 A; ProntoSil C18AQ by Nano LCMS Solutions). The sample was loaded onto a trap column of the same packing material for 5 min at 10 µ l min −1 before the elution gradient. The flow rate was 800 nl min. One microliter of sample was injected. The mass spectrometry (MS) data were acquired in triplicate using a Bruker Impact HD Q-TOF mass spectrometer in nano-booster mode with the following criteria: mass range 150-2,200 m/z, scan rate 2.0 Hz, precursor cycle time 3.0 s, absolute threshold 500 counts, 0% relative threshold, exclude after one spectrum and release after 2 min, and reconsider precursor if the ration of current intensity to previous intensity is 3.0. The MS/MS spectra were run against the Swiss-Prot human database with ProteinScape 4.0 (Bruker) using Mascot software. Trypsin cleavage specificity was set with a maximum of two missed cleavages allowed, and variable cysteinyl carbamidomethylation, deamidation (NQ) and oxidized methionine modifications were allowed. Peptide tolerance was set to 10.0 p.p.m. and a MS/MS tolerance to 0.5 Da. Peptides must be at least five amino acids long, and proteins were accepted with a Mascot score of > 40, and peptides were accepted with a Mascot score > 20.
Assay of proteins bound to nanoparticles. A solution of PBS with 1 mg ml −1 (Fe or drug) of SPIO nanoworms, Feraheme, LipoDox or Onivyde was incubated at a 1:3 volume ratio with serum or plasma for 30 min in a 37 °C water bath. Following incubation, samples were washed 5 times with PBS at 4 °C using ultracentrifuge as described above for proteomic studies. To determine the amount of specific proteins bound to nanoparticles, a quantitative immuno dot blot assay was used as described 15, 18, 24, 28 . Briefly, the pellets were resuspended in PBS, and 2 µ l of each sample was pipetted in triplicates onto a nitrocellulose membrane (0.45 µ m pore, Bio-Rad). Standard 2-fold dilutions of purified protein standards were applied to the same membrane (2 µ l dots in triplicate). Calibrated 2 µ l volume Eppendorf pipette was used for dot application. The membranes were blocked with a blocking buffer of 5% w/w nonfat dry milk in PBS-T (1x PBS and 0.1% v/v Tween-20) for 1 h at room temperature, probed with the primary antibody for 1 h at room temperature, followed by washes (three times) with PBS-T. Lastly, the membranes were probed with corresponding secondary antibody labelled with IRDye 680 or IRDye 800 (1:20,000 in blocking buffer) for 1 h at room temperature and washed three times with PBS-T. The membranes were scanned using the Odyssey infrared imager (Li-COR Biosciences) at either 700 nm or 800 nm depending on the label of secondary antibodies. For dot blot quantification, the background of 16-bit greyscale images was subtracted and integrated densities of the dots were measured with ImageJ software. The number of protein molecules per dot was determined from a standard curve of a protein dotted on the same membrane. Number of protein molecules per mg nanoparticle was calculated by dividing the number of molecules/dot by the amount of nanoparticles (mg Fe or mg drug) applied per dot. The previously calculated molar concentrations of nanoparticles and liposomes per mg Fe or drug 18 were used. For non-reducing Western blot, proteins were eluted from washed nanoparticle pellet with 2% SDS in PBS for 1 h at room temperature, the particles were pelleted with ultracentrifuge, the supernatant was mixed with Bio-Rad sample buffer without beta-mercaptoethanol and separated on a 4-20% Tris-Glycine SDS-PAGE. For reducing Western blot, nanoparticles after washing were resuspended in reducing sample buffer, boiled for 2 min at 95 °C and separated on a 4-20% Tris-Glycine SDS-PAGE. The proteins were transferred to nitrocellulose membrane, and processed as described for dot blot assay above. For detection of C3 and IgG on the same membrane, first C3 was detected with IRDye-800CW-labelled antibody, then the membrane was washed and IgG was detected with IRDye-680-labelled antibody. Both dyes were detected by scanning membrane at 700 and 800 nm with Li-COR Odyssey.
Preincubation of proteins with SPIO nanoworms.
Purified protein solutions in PBS or in the vendors' buffers (kininogen 1 mg ml −1 , fibronectin 1 mg ml −1 , fibrinogen 1 mg ml −1 , factor H 1 mg ml −1 , properdin 1 mg ml −1 , human serum albumin 50 mg ml −1 , Apo-B100 1.9 mg ml −1 , IgG 11.6 mg ml −1 , HDL 1 mg ml −1 and LDL 1 mg ml −1 ), or control PBS or the corresponding proteins' buffer in the same volume were preincubated with SPIO nanoworms (1 mg ml −1 in PBS) at a 1:1 v/v ratio for 15 min at room temperature. Following preincubation, serum was added to the nanoparticles at a 3:2 volume ratio, and the nanoparticles were incubated, washed and assayed for bound C3 as described for dot blot assay. The experiments were performed in three different sera for each tested protein.
Immunoglobulin depletion and reconstitution. To deplete serum or plasma of immunoglobulin (predominantly IgG), 0.05 g of dry protein A sepharose was added to a 1.7 ml Eppendorf tube. Next, 500 µ l of PBS was added to each tube, and beads were allowed to swell for 30 min at room temperature. At the end of the swelling period, tubes were centrifuged at 3,000g for 1 min and supernatant was removed from the slurry with a capillary gel-loading tip until the beads became almost dry (minimal carryover volume) and placed on ice. Freshly thawed cooled serum or lepirudin plasma (200 µ l) was added and gently agitated on a thermal mixer for 30 min at 4 °C to limit complement activation. Following agitation, samples were centrifuged for 1 min at 3,000g at 4 °C. Supernatant was carefully removed with a capillary gel-loading tip (without aspirating the slurry) and stored in aliquots at − 80 °C. For reconstitution, human IgG, IgM or trastuzumab (stock concentrations between 11.6 mg ml −1 and 14 mg ml −1 ) or PBS (control) were added to depleted sera or plasma in a 1:3 ratio and incubated at room temperature for 15 min, before addition of nanoparticles. Adult serum IgG levels are 767-1,590 mg dl −1 or 7.67-15.9 mg ml −1 . IgM serum levels are 37-286 mg dl −1 , or 0.37-2.86 mg ml −1 . Given the limitation of stock concentration of IgG and IgM (between 11.6 mg ml −1 and 14 mg ml −1 ), the final immunoglobulin levels were 2.9-3.5 mg ml −1 , which is lower than native IgG but similar to native IgM levels. Three different batches of purified IgG and one batch of purified IgM and one batch of trastuzumab were used for reconstitution experiments. The particles were incubated, washed and analysed with dot blot or Western blot as described above.
Complement inhibition studies.
To distinguish between pathways of complement activation, the inhibitor of Ca 2+ -sensitive pathways EGTA/Mg 2+ (10 mM EDTA and 10 mM MgCl final concentration), the inhibitor of both the alternative pathway and calcium-sensitive pathways EDTA (10 mM final concentration), the inhibitor of classical pathway C1INH (2.2 µ M final concentration) or 1× PBS (control) was added to sera or plasma samples at room temperature 30 min prior to the experiment. Purified factor H was added to sera at 1:10 ratio for a final 1 nature research | reporting summary 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
